 |
|
Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
Seungah Lee, Dong Yun Lee
Ann Pediatr Endocrinol Metab. 2017;22(1):15-26. Published online 2017 Mar 31 DOI: https://doi.org/10.6065/apem.2017.22.1.15
|
|
Citations to this article as recorded by
 Remolding probiotics for effective treatment of type 2 diabetes via oral administration
Haihua Ji, Yiqun Wan, Shengjie Li, Dexi Zhou, Fengying Gu, Jiajiu Sun, Xiaochen Yan, Yu Le, Tingtao Chen, Shaoping Nie, Hao Wan
Biomaterials.2025; 315: 122970. CrossRef Recent advances in incretin-based therapy for MASLD: from single to dual or triple incretin receptor agonists
Giovanni Targher, Alessandro Mantovani, Christopher D Byrne, Herbert Tilg
Gut.2025; 74(3): 487. CrossRef Exploring the Role of GLP-1 Receptor Agonists in Alzheimer’s Disease: A Review of Preclinical and Clinical Evidence
Lívia C. R. Teixeira, Marcelo R. Luizon, Karina B. Gomes
Receptors.2025; 4(1): 2. CrossRef Dietary bioactive compounds for type 2 diabetes: A comprehensive review of molecular interactions and mechanistic insights
Oumayma Aguerd, Hamza Elhrech, Meryem El Fessikh, Khan Wen Goh, Nasreddine El Omari, Tarik Aanniz, Abdelhakim Bouyahya
Journal of Functional Foods.2025; 126: 106705. CrossRef The pleiotropic effects of glucagon-like peptide-1 receptor agonists in patients with metabolic dysfunction-associated steatohepatitis: a review for gastroenterologists
Naim Alkhouri, Michael Charlton, Meagan Gray, Mazen Noureddin
Expert Opinion on Investigational Drugs.2025;[Epub] CrossRef Current Status of Microneedle Array Technology for Therapeutic Delivery: From Bench to Clinic
Chiranjib Chakraborty, Manojit Bhattacharya, Sang-Soo Lee
Molecular Biotechnology.2024; 66(12): 3415. CrossRef Current Status of Therapeutic Peptides for the Management of Diabetes Mellitus
Arvee Prajapati, Dhwani Rana, Shagun Rangra, Anil B. Jindal, Derajram Benival
International Journal of Peptide Research and Therapeutics.2024;[Epub] CrossRef The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer
Shahad Sabaawi Ibrahim, Raghad Sabaawi Ibrahim, Batoul Arabi, Aranka Brockmueller, Mehdi Shakibaei, Dietrich Büsselberg
Cancer and Metastasis Reviews.2024; 43(4): 1297. CrossRef Pharmacotherapy of Weight‐loss and Obesity with a Focus on GLP 1‐Receptor Agonists
Merle Myerson, Rodis D. Paparodis
The Journal of Clinical Pharmacology.2024; 64(10): 1204. CrossRef Machine-Learning-Guided Peptide Drug Discovery: Development of GLP-1 Receptor Agonists with Improved Drug Properties
Jens Christian Nielsen, Claudia Hjo̷rringgaard, Mads Mo̷rup Nygaard, Anita Wester, Lisbeth Elster, Trine Porsgaard, Randi Bonke Mikkelsen, Silas Rasmussen, Andreas Nygaard Madsen, Morten Schlein, Niels Vrang, Kristoffer Rigbolt, Louise S. Dalbo̷ge
Journal of Medicinal Chemistry.2024; 67(14): 11814. CrossRef Therapeutic Potential of Various Intermittent Fasting Regimens in Alleviating Type 2 Diabetes Mellitus and Prediabetes: A Narrative Review
Sthembiso Msane, Andile Khathi, Aubrey Sosibo
Nutrients.2024; 16(16): 2692. CrossRef GLP-1/GIP Agonist as an Intriguing and Ultimate Remedy for Combating
Alzheimer’s Disease through its Supporting DPP4 Inhibitors: A Review
Mohammad Abubakar, Lokesh Nama, Mohammad Arif Ansari, Mohammad Mazharuddin Ansari, Shivani Bhardwaj, Rajni Daksh, Katta Leela Venkata Syamala, Mohini Santosh Jamadade, Vishal Chhabra, Dileep Kumar, Nitesh Kumar
Current Topics in Medicinal Chemistry.2024; 24(19): 1635. CrossRef Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Basile Njei, Yazan Al-Ajlouni, Samira Y Lemos, Derek Ugwendum, Prince Ameyaw, Lea-Pearl Njei, Sarpong Boateng
Cureus.2024;[Epub] CrossRef Antidiabetic Drugs and their Potential Use in COVID-19: A Mechanistic
Approach
Bryan Alejandro Espinosa-Rodriguez, Aissa Michelle Nieto-Moreno, Jose Luis Gonzalez Llerena, Tania Alejandra Rico-Torres, Pilar Carranza-Rosales, Luis Fernando Mendez-Lopez, Isaias Balderas-Renteria
Endocrine, Metabolic & Immune Disorders - Drug Targets.2023; 23(3): 255. CrossRef Dulaglutide (Trulicity)-Induced Acute Pancreatitis: A Case Report
Abu baker Khan, Aimal Shah, Saad Ahmad, Moiz I Khan, Ahsan Amir
Cureus.2023;[Epub] CrossRef Metabolism and Excretion of Therapeutic Peptides: Current Industry Practices, Perspectives, and Recommendations
Minxia Michelle He, Sean Xiaochun Zhu, Joe R. Cannon, Jesper Kammersgaard Christensen, Ruchia Duggal, Mithat Gunduz, Constanze Hilgendorf, Adam Hughes, Ivy Kekessie, Maximilian Kullmann, Dennis Leung, Carsten Terjung, Kai Wang, Frank Wesche
Drug Metabolism and Disposition.2023; 51(11): 1436. CrossRef Glucagon-related advancements in diabetes therapy
Binayak Sinha, Samit Ghosal, Satinath Mukhopadhyay, Akhtar Hussain, Anjana Ranjit Mohan, Peter Schwarz, Francesc Xavier Cos Xavier
Journal of Diabetology.2023; 14(Supplement): S16. CrossRef Dulaglutide Ameliorates Palmitic Acid-Induced Hepatic Steatosis by Activating FAM3A Signaling Pathway
Jinmi Lee, Seok-Woo Hong, Min-Jeong Kim, Sun Joon Moon, Hyemi Kwon, Se Eun Park, Eun-Jung Rhee, Won-Young Lee
Endocrinology and Metabolism.2022; 37(1): 74. CrossRef Absorption, Distribution, Metabolism, and Excretion of Therapeutic Proteins: Current Industry Practices and Future Perspectives
Jayaprakasam Bolleddula, Kevin Brady, Gerard Bruin, Anthony Lee, Jennifer A. Martin, Markus Walles, Keyang Xu, Tong-Yuan Yang, Xiaochun Zhu, Hongbin Yu
Drug Metabolism and Disposition.2022; 50(6): 837. CrossRef A Cross Company Perspective on the Assessment of Therapeutic Protein Biotransformation
Markus Walles, Michael Berna, Wenying Jian, Simon Hauri, Shawna Hengel, Lloyd King, John C. Tran, Cong Wei, Keyang Xu, Xiaochun Zhu
Drug Metabolism and Disposition.2022; 50(6): 846. CrossRef Role of Glucagon-like Peptide-1 (GLP-1) Agonists in the Management of Diabetic Patients with or without COVID-19
Fatemeh Mirzaei, Iraj Khodadadi, Nesrine Majdoub, Seyyed Alireza Vafaei, Heidar Tayebinia, Ebrahim Abbasi
The Open Medicinal Chemistry Journal.2022;[Epub] CrossRef Liraglutide treatment and acylcarnitine profiles in Egyptian obese insulin-resistant females
Neveen A. Hussein, Samia A. Ebied, Hoda A. Nour, Usama K. Zaki, Sahar M. EL-Kotishy, Tarek M. Salem
European Journal of Pharmacology.2021; 891: 173668. CrossRef Choline‐Geranate Deep Eutectic Solvent Improves Stability and Half‐Life of Glucagon‐Like Peptide‐1
Christian Agatemor, Tyler D. Brown, Yongsheng Gao, Naoya Ohmori, Kelly N. Ibsen, Samir Mitragotri
Advanced Therapeutics.2021;[Epub] CrossRef GLP-1 Val8: A Biased GLP-1R Agonist with Altered Binding Kinetics and Impaired Release of Pancreatic Hormones in Rats
Wijnand J. C. van der Velden, Florent X. Smit, Charlotte B. Christiansen, Thor C. Møller, Gertrud M. Hjortø, Olav Larsen, Sine P. Schiellerup, Hans Bräuner-Osborne, Jens J. Holst, Bolette Hartmann, Thomas M. Frimurer, Mette M. Rosenkilde
ACS Pharmacology & Translational Science.2021; 4(1): 296. CrossRef Biased agonists with less glucagon-like peptide-1 receptor-mediated endocytosis prolong hypoglycaemic effects
Qiang Wu, Song Chen, Hanchen Zhu, Na Xu, Qianhua Yang, Wenbing Yao, Xiangdong Gao
European Journal of Pharmacology.2021; 907: 174203. CrossRef An overview of the neuroendocrine system in Parkinson’s disease: what is the impact on diagnosis and treatment?
Agata Mulak
Expert Review of Neurotherapeutics.2020; 20(2): 127. CrossRef GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists
José Luis Górriz, María José Soler, Juan F. Navarro-González, Clara García-Carro, María Jesús Puchades, Luis D’Marco, Alberto Martínez Castelao, Beatriz Fernández-Fernández, Alberto Ortiz, Carmen Górriz-Zambrano, Jorge Navarro-Pérez, Juan José Gorgojo-Mar
Journal of Clinical Medicine.2020; 9(4): 947. CrossRef Clinically established biodegradable long acting injectables: An industry perspective
Christian Isalomboto Nkanga, Andreas Fisch, Mazda Rad-Malekshahi, Marieta Duvnjak Romic, Birgit Kittel, Thomas Ullrich, Jing Wang, Rui Werner Maçedo Krause, Sabine Adler, Twan Lammers, Wim E. Hennink, Farshad Ramazani
Advanced Drug Delivery Reviews.2020; 167: 19. CrossRef Obesidad y diabetes mellitus tipo 2: también unidas en opciones terapéuticas
Matilde Rubio-Almanza, Rosa Cámara-Gómez, Juan Francisco Merino-Torres
Endocrinología, Diabetes y Nutrición.2019; 66(3): 140. CrossRef Narrative review of the effects of antidiabetic drugs on albuminuria
Habib Yaribeygi, Stephen L. Atkin, Niki Katsiki, Amirhossein Sahebkar
Journal of Cellular Physiology.2019; 234(5): 5786. CrossRef Anti-inflammatory and pro-healing impacts of exendin-4 treatment in Zucker diabetic rats: Effects on skin wound fibroblasts
Monika Wolak, Teresa Staszewska, Marlena Juszczak, Małgorzata Gałdyszyńska, Ewa Bojanowska
European Journal of Pharmacology.2019; 842: 262. CrossRef Does obesity cause type 2 diabetes mellitus (T2DM)? Or is it the opposite?
John I. Malone, Barbara C. Hansen
Pediatric Diabetes.2019; 20(1): 5. CrossRef Obesity and type 2 diabetes: Also linked in therapeutic options
Matilde Rubio-Almanza, Rosa Cámara-Gómez, Juan Francisco Merino-Torres
Endocrinología, Diabetes y Nutrición (English ed.).2019; 66(3): 140. CrossRef GLP-1 Receptor in Pancreatic α-Cells Regulates Glucagon Secretion in a Glucose-Dependent Bidirectional Manner
Yanqing Zhang, Keshab R. Parajuli, Genevieve E. Fava, Rajesh Gupta, Weiwei Xu, Lauren U. Nguyen, Anadil F. Zakaria, Vivian A. Fonseca, Hongjun Wang, Franck Mauvais-Jarvis, Kyle W. Sloop, Hongju Wu
Diabetes.2019; 68(1): 34. CrossRef Exenatide extended-release pre-filled pen (Bydureon® BCise®): a profile of its use
Emma D. Deeks
Drugs & Therapy Perspectives.2019; 35(2): 51. CrossRef Feasibility, Adherence and Efficacy of Liraglutide Treatment in a Sample of Individuals With Mood Disorders and Obesity
Alessandro Cuomo, Simone Bolognesi, Arianna Goracci, Cristina Ciuoli, Bruno Beccarini Crescenzi, Giuseppe Maina, Gianluca Rosso, Edvige Facchi, Carla Maccora, Nicola Giordano, Valeria Verdino, Andrea Fagiolini
Frontiers in Psychiatry.2019;[Epub] CrossRef Treatment patterns, glycemic control and bodyweight with canagliflozin 300 mg versus GLP1RAs in Type II diabetes patients
Craig I Coleman, Shivani Pandya, Li Wang, Onur Baser, Jennifer Cai, Mike Ingham, Brahim Bookhart
Journal of Comparative Effectiveness Research.2019; 8(11): 889. CrossRef Neuroprotective Effects of Brain-Gut Peptides: A Potential Therapy for Parkinson’s Disease
Dong Dong, Junxia Xie, Jun Wang
Neuroscience Bulletin.2019; 35(6): 1085. CrossRef The role of Leu260Phe polymorphism of the receptor gene to GLP-1 incretin in the pathogenesis of diabetes type 2 diabetes with obesity
Daria A. Skuratovskaia, Maria A. Vulf, Elena V. Kirienkova, Natalia I. Myronyuk, Pavel A. Zatolokin, Larisa S. Litvinova
Diabetes mellitus.2019; 22(3): 217. CrossRef Mono-PEGylates of exenatide in branched and dimeric structures can improve in vivo stability and hypoglycemic bioactivity
Ngoc-Thanh Thi Nguyen, Sujin Jung, Seung Hwan Lee, Ok Nam Bae, E.K. Lee
Journal of Biotechnology.2019; 306: 89. CrossRef Association Between Exercise and Treatment with Liraglutide in Obese Rats by Cafeteria Diet
Daiane Didek, Maiara Mikuska Cordeiro, João Lucas de Paula Xavier, Paulo Roberto Ribeiro, Thiago Rentz, Gilson Cesar Nobre Franco, Carla Cristine Kanunfre, Henriette Rosa de Oliveira Emilio, Dionízia Xavier Scomparin
Brazilian Archives of Biology and Technology.2019;[Epub] CrossRef Glutazumab, a novel long-lasting GLP-1/anti-GLP-1R antibody fusion protein, exerts anti-diabetic effects through targeting dual receptor binding sites
Caina Li, Miaomiao Yang, Xiaofeng Wang, Hua Zhang, Chenjiang Yao, Sujuan Sun, Quan Liu, Hao Pan, Shuainan Liu, Yi Huan, Shengnan Li, Jun Cao, Xing Wang, Yong Guo, Nan Guo, Shuqian Jing, Cheng Zhang, Zhufang Shen
Biochemical Pharmacology.2018; 150: 46. CrossRef Chrysophanol Relieves Cognition Deficits and Neuronal Loss Through Inhibition of Inflammation in Diabetic Mice
Xu Chu, Shuhu Zhou, Ran Sun, Lin Wang, Chunye Xing, Ruqing Liang, Qingxia Kong
Neurochemical Research.2018; 43(4): 972. CrossRef Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists
Yehuda Handelsman, Kathleen Wyne, Anthony Cannon, Michael Shannon, Doron Schneider
Journal of Managed Care & Specialty Pharmacy.2018; 24(9-a Suppl): S14. CrossRef Cardiovascular Outcomes with Once-Weekly GLP-1 RAs: Clinical and Economic Implications
Michael Heile, Kathleen Wyne, Liana K. Billings, Anthony Cannon, Yehuda Handelsman, Michael Shannon
Journal of Managed Care & Specialty Pharmacy.2018; 24(9-a Suppl): S42. CrossRef
|